S
Ludwig Hantson
CEO, US Pharmaceuticals, Novartis
PROMOTED: April 2008
The most recent promotion in CEO Daniel Vasella's executive shake-up is Novartis veteran Ludwig Hantson, PhD, the brand new head of the Swiss giant's US business. Hantson, 45, is likely as close to a white knight as Novartis has—fresh from prior stints leading the US specialty drug unit and Europe's pharma business. The new gig should offer him the opportunity to show off his sharp skills dealing with penny-pinching payers.
Ludwig Hantson
And based on his track record, it could also lead to bigger things. No one at Novartis is better prepped to succeed Vasella in the top job. Over 22 years, Hantson has hop-scotched from humble sales rep to clinical development to marketing maven to management. "I was eager to learn, so I chose to move from one function to another, sometimes starting from scratch," he says. "I took risks."
Cross-functional, global, risk-taking—that's pharma's future in shorthand. But first Hantson has to pass his toughest test—making Wall Street smile on Novartis again by reversing its plunge in US sales. "We need to get closer to the customer, whether that's patients, physicians, or payers, and build their needs into our strategic plans," he says.
One month in, he's getting good grades from Café Pharma posters, but no word yet from Basel. When asked if he would like to be CEO of a large-cap, Hantson plays it straight. "That's a rhetorical question," he says. "Of course. Otherwise I wouldn't be sitting here."
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.